Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
25
5
2022
medline:
28
7
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV. Cross-sectional study. We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. We calculated TB signatures using gene expression data from qRT-PCR. We used multivariable linear regression to analyze the association between prior receipt of IPT or NTM sputum culture positivity with a transcriptional TB risk score, RISK6 (range 0-1). In secondary analyses, we explored the association between IPT or NTM positivity and four other TB transcriptional signatures. Among 381 participants, 99.7% were receiving antiretroviral therapy and 86.6% had received IPT (completed median of 1.1 years prior). RISK6 scores were lower (mean difference 0.10; 95% confidence interval (CI): 0.06-0.15; P < 0.001) among participants who received IPT than those who did not. In a model that adjusted for age, sex, duration of ART, and plasma HIV RNA, the RISK6 score was 52.8% lower in those with a history of IPT ( P < 0.001). No significant association between year of IPT receipt and RISK6 scores was detected. There was no association between NTM sputum culture positivity and RISK6 scores. In people with HIV, IPT was associated with significantly lower RISK6 scores compared with persons who did not receive IPT. These data support investigations of its performance as a TB preventive therapy response biomarker.
Identifiants
pubmed: 35608118
doi: 10.1097/QAD.0000000000003262
pii: 00002030-202208010-00005
pmc: PMC9329226
mid: NIHMS1799076
doi:
Substances chimiques
Antitubercular Agents
0
Isoniazid
V83O1VOZ8L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1363-1371Subventions
Organisme : NIAID NIH HHS
ID : K24 AI137310
Pays : United States
Organisme : FIC NIH HHS
ID : D43 TW010559
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization. Global Tuberculosis Report 2021. Geneva, Switzerland: World Health Organization.
World Health Organization. WHO operational handbook on tuberculosis. Module 1: prevention - tuberculosis preventive treatment. License: CC BY-NC-SA 3.0 IGO. 2020.
Getahun H, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection . N Engl J Med 2015; 373:1179–1180.
Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children . Clin Infect Dis 2017; 64:e1–e33.
Nasiri MJ, Pormohammad A, Goudarzi H, Mardani M, Zamani S, Migliori GB, et al. Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA . Infection 2019; 47:353–361.
Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis . J Acquir Immune Defic Syndr 2011; 56:230–238.
Nemes E, Rozot V, Geldenhuys H, Bilek N, Mabwe S, Abrahams D, et al. C-040-404 Study Team and the Adolescent Cohort Study Team Optimization and Interpretation of Serial QuantiFERON Testing to measure acquisition of Mycobacterium tuberculosis infection . Am J Respir Crit Care Med 2017; 196:638–648.
Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? . Int J Tuberc Lung Dis 2006; 10:1192–1204.
Biraro IA, Egesa M, Kimuda S, Smith SG, Toulza F, Levin J, et al. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study . BMC Infect Dis 2015; 15:438.
Clifford V, He Y, Zufferey C, Connell T, Curtis N. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: a systematic review . Tuberculosis (Edinb) 2015; 95:639–650.
World Health Organization. Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva, Switzerland: World Health Organization; 2017.
Sutherland JS, van der Spuy G, Gindeh A, Thuong NT, Namuganga AR, Owolabi O, et al. Diagnostic accuracy of the Cepheid 3-gene host response fingerstick blood test in a prospective, multisite study: interim results . Clin Infect Dis 2021; [Epub ahead of print].
Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis . Lancet Respir Med 2016; 4:213–224.
Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, et al. Host blood RNA signatures predict the outcome of tuberculosis treatment . Tuberculosis (Edinb) 2017; 107:48–58.
Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al. SATVI Clinical Immunology Team Detection of tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV-infected persons on antiretroviral therapy . Front Microbiol 2019; 10:1441.
Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et al. CORTIS-HR Study Team Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study . Lancet Glob Health 2021; 9:e841–e853.
Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, et al. Scriba TJ, Adolescent Cohort Study team, GC6-74 Consortium, SATVI Clinical and Laboratory Team, ScreenTB Consortium, AE-TBC Consortium, RePORT Brazil Team, Peruvian Household Contacts Cohort Team, CAPRISA IMPRESS team RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response . Sci Rep 2020; 10:8629.
Suliman S, Thompson EG, Sutherland J, Weiner J, Ota MOC, Shankar S, et al. GC6-74 cohort study team, The ACS cohort study team Four-gene Pan-African blood signature predicts progression to tuberculosis . Am J Respir Crit Care Med 2018; 197:1198–1208.
Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. ACS and GC6-74 cohort study groups A blood RNA signature for tuberculosis disease risk: a prospective cohort study . Lancet 2016; 387:2312–2322.
Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection . Clin Microbiol Rev 2018; 31:e00021-18.
Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives . Tuberc Respir Dis (Seoul) 2016; 79:74–84.
Kobayashi T, Nishijima T, Teruya K, Aoki T, Kikuchi Y, Oka S, Gatanaga H. High mortality of disseminated non-tuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era . PLoS One 2016; 11:e0151682.
Cowman SA, Jacob J, Hansell DM, Kelleher P, Wilson R, Cookson WOC, et al. Whole-blood gene expression in pulmonary nontuberculous mycobacterial infection . Am J Respir Cell Mol Biol 2018; 58:510–518.
Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, et al. Pulmonary tuberculosis screening in antiretroviral treated adults living with HIV in Kenya . BMC Infect Dis 2021; 21:218.
van’t Hoog AH, Laserson KF, Githui WA, Meme HK, Agaya JA, Odeny LO, et al. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western Kenya . Am J Respir Crit Care Med 2011; 183:1245–1253.
Khoury MJ, Beaty TH, Hwang SJ. Detection of genotype-environment interaction in case-control studies of birth defects: how big a sample size? . Teratology 1995; 51:336–343.
Maertzdorf J, McEwen G, Weiner J, Tian S, Lader E, Schriek U, et al. Concise gene signature for point-of-care classification of tuberculosis . EMBO Mol Med 2016; 8:86–95.
Maertzdorf J, Weiner J, Mollenkopf HJ, Bauer T, Prasse A, Müller-Quernheim J, Kaufmann SH. Common patterns and disease-related signatures in tuberculosis and sarcoidosis . Proc Natl Acad Sci U S A 2012; 109:7853–7858.
Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, et al. CORTIS-01 Study Team Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial . Lancet Infect Dis 2021; 21:354–365.
Mulenga H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, Kimbung Mbandi S, Fiore-Gartland A, et al. CORTIS Study Team Longitudinal dynamics of a blood transcriptomic signature of tuberculosis . Am J Respir Crit Care Med 2021; 204:1463–1472.
Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection . N Engl J Med 2011; 365:11–20.
Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, et al. Tuberculosis incidence after 36 months’ isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis . AIDS 2015; 29:351–359.
Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases . Am J Respir Crit Care Med 2007; 175:367–416.